Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of urothelial (transitional cell) carcinoma with the exception of micropapillary subtype~* Patients must have recurrent disease (locally advanced or metastatic) that is not amenable to local therapy or newly diagnosed distant metastatic disease~* Measurable disease defined by RECIST v.1.0~* ECOG performance status of 2 or better~* Adequate organ and bone marrow function defined as~Exclusion Criteria:~* Other tumor type than urothelial carcinoma~* Presence or history of CNS metastasis~* Prior systemic chemotherapy or immunotherapy (but prior local intravesical chemotherapy or immunotherapy was allowed. And recurrent disease after adjuvant or neoadjuvant cisplatin-based systemic chemotherapy is allowed if the last chemotherapy was administered 1 year or more before the patient enrollment.)~* Presence of second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)~* Peripheral sensory neuropathy grade 2 or worse~* Other serious illness or medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PemCis (Type: EXPERIMENTAL): Pemetrexed plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).